Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  € $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

Infectives Partnering Terms and Agreements

Enquire | Email | Print

Published Date: Mar, 2014
Format: PDF
No of Pages: 803
 
 
Select pricing :
Change Currency: € EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

The Infectives Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter infectives partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors infectives technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 2,000 links to online copies of actual infectives deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of infectives dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in infectives dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading infectives deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of infectives deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all infectives deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all infectives partnering deals signed and announced since 2009. The chapter is organized by specific infectives therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all infectives partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in infectives partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of infectives technologies and products.

Report scope

Infectives Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to infectives trends and structure of deals entered into by leading companies worldwide.

Infectives Partnering Terms and Agreements includes:
Trends in infectives dealmaking in the biopharma industry since 2009
Analysis of infectives deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of infectives deal contract documents
Comprehensive access to over 2,000 infectives deal records
The leading infectives deals by value since 2009
Most active infectives dealmakers since 2009
In Infectives Partnering Terms and Agreements, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Infectives Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 2,000 infectives deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise infectives rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Infectives Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of infectives deal trends since 2009
Access infectives deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between infectives partner companies
Comprehensive access to over 2,000 links to actual infectives deals entered into by the world’s biopharma companies
Indepth review of infectives deals entered into by the leading fifty bigpharma companies
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner infectives opportunities
Uncover companies actively partnering infectives opportunities 

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in infectives dealmaking

2.1. Introduction
2.2. Infectives partnering over the years
2.3. Bigpharma infectives dealmaking activity
2.4. Bigpharma not active in infectives
2.5. Infectives partnering by deal type
2.6. Infectives partnering by industry sector
2.7. Infectives partnering by stage of development
2.8. Infectives partnering by technology type
2.9. Infectives partnering by infectives indication
2.10. Average deal terms for infectives
2.10.1 Infectives headline values
2.10.2 Infectives upfront payments
2.10.3 Infectives milestone payments
2.10.4 Infectives royalty rates
Chapter 3 – Leading infectives deals

3.1. Introduction
3.2. Top infectives deals by value
3.3. Top infectives deals involving bigpharma
Chapter 4 – Bigpharma infectives deals

4.1. Introduction

4.2. How to use bigpharma partnering deals

4.3. Bigpharma infectives partnering company profiles

Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
UCB
Valeant
Warner Chilcott
Watson
Chapter 5 – Infectives partnering contracts directory

5.1. Introduction

5.2. By deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Sub-license
Supply
Technology transfer
Termination
Warranty
5.3. By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
5.4. By technology type
Adjuvant
Animal models
Antibodies
Monoclonal antibodies
Humanized mAb
Human mAb
Assays
Biodefense
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Devices
Diagnostics
Discovery tools
Drug delivery
Enabling technology
Equipment
Facilities
Genomics
Industrial chemicals
Natural product
Oligonucleotide
Orphan drug
Packaging
Pediatrics
Peptides
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Software tools
Stem cells
Vaccines
5.5. By therapeutic indication
Infectives
Bacterial
Anthrax
Escherichia Coli (E-coli)
Haemophilus influenzae type b (Hib)
Methicillin-resistant Staphylococcus aureus (MRSA)
Pertussis (Whooping Cough)
Pseudomonas aeruginosa
Sepsis
Tuberculosis (TB)
Fungal
Onychomycosis (Nail infection)
Parasitic
Tropical
Dengue fever
Malaria
Viral
Common cold
Ebola
Foot and mouth disease
Hepatitis A
Hepatitis B
Hepatitis C
Herpes simplex
HIV
Influenza
H5N1 (Avian Flu)
Japanese encephalitis
Respiratory syncytial virus (RSV)
Chapter 6 – Infectives dealmaking by indication

6.1. Introduction
6.2. Deals by therapeutic indication
Infectives
Bacterial
Anthrax
Campylobacter Jejuni
Clostridium difficile
Diphtheria
Escherichia Coli (E-coli)
Group A Streptococcus
Group B Streptococcus
Haemophilus influenzae type b (Hib)
Helicobacter Pylori
Lyme disease
Methicillin-resistant Staphylococcus aureus (MRSA)
Mycobacterium avium
Pertussis (Whooping Cough)
Pseudomonas aeruginosa
Salmonella
Sepsis
Tetanus
Tuberculosis (TB)
Fungal
Nail Psoriasis
Onychomycosis (Nail infection)
Parasitic
Tropical
African trypanosomiasis (Sleeping sickness)
Dengue fever
Malaria
Yellow fever
Viral
Common cold
Cytomegalovirus
Ebola
FIV
Foot and mouth disease
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Herpes simplex
HIV
Influenza
H1N1 (Swine Flu)
H5N1 (Avian Flu)
Japanese encephalitis
Polio
Respiratory syncytial virus (RSV)
Chapter 7 – Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
About Wildwood Ventures

Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Appendix

Appendix 1 – Directory of infectives deals by company A-Z 2009-2014
Appendix 2 – Directory of infectives deals by deal type 2009-2014
Appendix 3 – Directory of infectives deals by stage of development 2009-2014
Appendix 4 – Directory of infectives deals by technology type 2009-2014
Appendix 5 – Deal type definitions

Table of Figures

Figure 1: Infectives partnering since 2009
Figure 2: Bigpharma – top 50 – infectives deals 2009 to 2012
Figure 3: Bigpharma infectives deal frequency – 2009 to 2012
Figure 4: Inactive bigpharma in infectives 2009-2014
Figure 5: Infectives partnering by deal type since 2009
Figure 6: Infectives partnering by industry sector since 2009
Figure 7: Infectives partnering by stage of development since 2009
Figure 8: Infectives partnering by technology type since 2009
Figure 9: Infectives partnering by infective target since 2009
Figure 10: Infectives deals with a headline value
Figure 11: Infectives deal headline value distribution, US$million – discovery stage
Figure 12: Infectives deal headline value distribution, US$million – preclinical stage
Figure 13: Infectives deal headline value distribution, US$million – phase I stage
Figure 14: Infectives deal headline value distribution, US$million – phase II stage
Figure 15: Infectives deal headline value distribution, US$million – phase III stage
Figure 16: Infectives deal headline value distribution, US$million – regulatory stage
Figure 17: Infectives deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2005-2014
Figure 19: Infectives deals with upfront payment values
Figure 20: Infectives deal upfront payment distribution, US$million – discovery stage
Figure 21: Infectives deal upfront payment distribution, US$million – preclinical stage
Figure 22: Infectives deal upfront payment distribution, US$million – phase I stage
Figure 23: Infectives deal upfront payment distribution, US$million – phase II stage
Figure 24: Infectives deal upfront payment distribution, US$million – phase III stage
Figure 25: Infectives deal upfront payment distribution, US$million – regulatory stage
Figure 26: Infectives deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2005-2014
Figure 28: Infectives deals with milestone payments
Figure 29: Infectives deal milestone distribution, US$million – discovery stage
Figure 30: Infectives deal milestone distribution, US$million – preclinical stage
Figure 31: Infectives deal milestone distribution, US$million – phase I stage
Figure 32: Infectives deal milestone distribution, US$million – phase II stage
Figure 33: Infectives deal milestone distribution, US$million – phase III stage
Figure 34: Infectives deal milestone distribution, US$million – regulatory stage
Figure 35: Infectives deal milestone distribution, US$million – marketed stage
Figure 36: Infectives deals with royalty rates, %
Figure 37: Infectives deal royalty rate distribution, US$million – discovery stage
Figure 38: Infectives deal royalty rate distribution, US$million – preclinical stage
Figure 39: Infectives deal royalty rate distribution, US$million – phase I stage
Figure 40: Infectives deal royalty rate distribution, US$million – phase II stage
Figure 41: Infectives deal royalty rate distribution, US$million – phase III stage
Figure 42: Infectives deal royalty rate distribution, US$million – regulatory stage
Figure 43: Infectives deal royalty rate distribution, US$million – marketed stage
Figure 44: Summary median royalty rate by stage of development, 2005-2014
Figure 45: Top infectives deals by value since 2009
Figure 46: Top infectives deals signed by bigpharma value since 2005
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events 

Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 328607, price: INR 182407, CurrentPartnering

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online